Dabrafenib: Also no added benefit over vemurafenib

Results from indirect comparison did not allow any reliable conclusions

2014-04-09

(Press-News.org) Dabrafenib (trade name: Tafinlar) has been approved since August 2013 for the treatment of advanced melanoma. In January 2014, in an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) had determined that dabrafenib has no added benefit in comparison with dacarbazine. IQWiG now assessed dabrafenib in comparison with vemurafenib. The report presented in the form of an addendum came to the same conclusion because the results from the indirect comparison presented by the drug manufacturer did not allow any reliable conclusions.

G-BA specified appropriate comparator therapy

Dabrafenib is an option for adult patients with melanoma that has a certain abnormal protein (BRAF V600 mutation) and that is unresectable or has already formed metastases.

In the first dossier assessment, the Federal Joint Committee (G-BA) had specified the drug dacarbazine as the appropriate comparator therapy. Hence IQWiG did not assess data on an indirect comparison with vemurafenib, which the manufacturer had also presented in the dossier. However, the G-BA subsequently commissioned IQWiG to consider these data and to assess the added benefit of dabrafenib versus vemurafenib because the G-BA specified vemurafenib as appropriate comparator therapy during the hearing procedure. It considered its current decision on vemurafenib and the evidence on dacarbazine in this specification.

Manufacturer used two approval studies

The manufacturer used data from the respective approval study on dabrafenib (BREAK-3) and on vemurafenib (BRIM-3) for the indirect comparison. The drugs were tested directly against dacarbazine in both studies. Dacarbazine could therefore be used as a so-called common comparator. Results on the outcomes "overall survival" and "adverse events (side effects)" were available from both studies.

Indirect comparison must fulfil certain requirements

It depends on various factors whether or not the results of such an indirect comparison are informative: On the one hand, the method must be suitable; on the other hand, the data used in the comparison have to fulfil certain minimum requirements regarding their risk of bias and their structural quality. With regard to the latter, it is decisive, among other things, whether the patients investigated in the studies are sufficiently similar.

Results on overall survival highly biased

The researchers found out that these requirements were not sufficiently fulfilled. It was unclear whether the patients investigated in the two studies were sufficiently similar in the prognosis of their disease.

The results on overall survival were highly biased: This was due to the fact that it was possible in one of the studies (BREAK-3) to switch to dabrafenib treatment (crossover) at an early stage. This already played an important role in the first dossier assessment of dabrafenib.

Regarding the outcome "side effects", the informative value of the indirect comparison was limited because patients within the studies, i.e. in the two study arms, were observed for different lengths of time.

An added benefit of dabrafenib compared with vemurafenib is therefore not proven.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and the IQWiG dossier assessment, the G-BA conducted a commenting procedure. If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The Institute sent the addendum on dabrafenib to the commissioning agency on 14 March 2014. The G-BA decided on the extent of the added benefit of dabrafenib on 3 April 2014, thus completing the early benefit assessment.

INFORMATION: END

ELSE PRESS RELEASES FROM THIS DATE:

ORNL study pegs fuel economy costs of common practices

2014-04-09

OAK RIDGE, Tenn., April 9, 2014 – People who pack their cars and drive like Clark Griswold in National Lampoon's "Vacation" pay a steep penalty when it comes to fuel economy, according to a report by the Department of Energy's Oak Ridge National Laboratory. For the study, researchers tested a sport utility vehicle and a compact sedan with various configurations, including underinflated tires, open windows, and rooftop and hitch-mounted cargo. The SUV, a 2009 Ford Explorer with a 4-liter V6 engine, was also tested while towing an enclosed trailer. The researchers tested ...

Love is a many-faceted thing

2014-04-09

Regular churchgoers, married people or those who enjoy harmonious social ties are most satisfied with their love life. This also goes for people who are currently in love or who experience the commitment and sexual desire of their partners, says Félix Neto and Maria da Conceição Pinto of the Universidade do Porto in Portugal. Their findings, published in an article in Springer's journal Applied Research in Quality of Life, look at the influences on love life satisfaction throughout one's adult life. The researchers associate love with the desire to enter into, maintain, ...

BU researchers identify specific causes of brown fat cell 'whitening'

2014-04-09

(Boston) – Boston University researchers have learned new information about the consequences of overeating high-calorie foods. Not only does this lead to an increase in white fat cell production, the type prominent in obesity, but it also leads to the dysfunction of brown fat cells, the unique type of fat that generates heat and burns energy. This study is the first to describe how overeating causes brown fat cells to "whiten." Published in the Journal of Clinical Investigation, the results illustrate the important role that a healthy diet plays in overall health and ...

JCI online ahead of print table of contents for April 8, 2014

2014-04-09

Visualizing calcium dynamics in the kidney In this issue of the Journal of Clinical Investigation, Janos Peti-Peterdi and colleagues at the University of Southern California used multiphoton microscopy (MPM) to directly visualize podocyte calcium dynamics within the intact kidneys of live mice. A robust calcium wave was generated in response to glomerular injury and this signal spread throughout cells. Mice lacking the P2Y2 purinergic receptor or treated with inhibitors of calcium signaling prevented propagation of a calcium wave. Furthermore, increased calcium signaling ...

Physical activity is beneficial for late-life cognition

2014-04-09

Physical activity in midlife seems to protect from dementia in old age, according to a study carried out at the University of Eastern Finland. Those who engaged in physical activity at least twice a week had a lower risk of dementia than those who were less active. The protective effects were particularly strong among overweight individuals. In addition, the results showed that becoming more physically active after midlife may also contribute to lowering dementia risk. Several modifiable risk factors for dementia have been suggested, but further refinement of this information ...

New research reveals the reality of adoption breakdowns

2014-04-09

The most comprehensive study ever to be carried out into adoption in England has confirmed that the rate of breakdown is lower than anticipated, but it also reveals a stark picture of the problems faced by families. Researchers from the University of Bristol analysed national data on 37,335 adoptions over a 12 year period to show that 3.2 per cent of children – around three in 100 - move out of their adoptive home prematurely, known as a 'disruption'. Adoptions were more likely to breakdown if a child was placed once they were over the age of four. Most adoptions breakdown ...

Study tests theory that life originated at deep sea vents

2014-04-09

One of the greatest mysteries facing humans is how life originated on Earth. Scientists have determined approximately when life began (roughly 3.8 billion years ago), but there is still intense debate about exactly how life began. One possibility - that simple metabolic reactions emerged near ancient seafloor hot springs, enabling the leap from a non-living to a living world – has grown in popularity in the last two decades. Recent research by geochemists Eoghan Reeves, Jeff Seewald, and Jill McDermott at Woods Hole Oceanographic Institution (WHOI) is the first to test ...

Refrigerant in cars: Refreshingly cool, potentially toxic

2014-04-09

The refrigerant R1234yf is being considered for use in air conditioning systems in cars. Chemists at Ludwig-Maximilians-Universitaet (LMU) in Munich now show that, in the event of a fire, it releases the highly poisonous carbonyl fluoride, and urge that its safety be reassessed. According to EU guidelines, the new compound R1234yf should in future be used as the refrigerant in air-conditioning systems for automobiles. But the compound is inflammable, and LMU chemists have now shown that combustion of the cooling agent leads to the formation of the highly toxic carbonyl ...

Chance meeting creates celestial diamond ring

2014-04-09

Most stars with masses similar to that of our Sun will end their lives as white dwarfs — small, very dense, and hot bodies that slowly cool down over billions of years. On the way to this final phase of their lives the stars throw their atmospheres out into the space and create planetary nebulae, colourful glowing clouds of gas surrounding the small, bright stellar relics. This image, captured by ESO's Very Large Telescope (VLT), shows the remarkably round planetary nebula Abell 33, located some 1500 light-years from Earth. Being perfectly round is uncommon for these ...

EASL publishes online recommendations on the management of hepatitis C

2014-04-09

London, UK, Wednesday 9 April 2014: The European Association for the Study of the Liver (EASL) will this week be announcing new on-line recommendations on the management of hepatitis C (HCV) at the International Liver Congress™ (ILC). These EASL recommendations reflect the approval of three new direct-acting antivirals (DAAs) during 2014 by the European Medicines Agency. It is estimated that approximately 185 million people are infected with HCV on a global scale, with approximately 150 million people living with chronic infection. In Europe, between 7.3 million and ...

Dabrafenib: Also no added benefit over vemurafenib

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: